Government tackled over why Grenfell cladding ‘crooks' not behind bars
Ministers have been pressed over why 'crooks' running a firm that made the cladding on Grenfell Tower that was devastated in a fire eight years ago are 'not behind bars'.
The call by Labour former minister Lord Rooker came after fresh evidence emerged that bosses at US-based manufacturing giant Arconic knew of the dangers posed by the highly flammable material prior to the 2017 disaster at the west London high-rise block, which claimed 72 lives.
It followed the release of documents secured through legal action by the makers of a forthcoming Netflix documentary, Grenfell: Uncovered, which were shared with The Sunday Times.
The final report of the Grenfell inquiry concluded each of the deaths was avoidable and had been preceded by 'decades of failure' by government and the building industry to act on the dangers of flammable materials on high-rise buildings.
It also found victims, the bereaved and survivors were 'badly failed' through incompetence, dishonesty and greed.
The tower block was covered in combustible products because of the 'systematic dishonesty' of firms who made and sold the cladding and insulation, inquiry chairman Sir Martin Moore-Bick said last year.
He also condemned the 'deliberate and sustained' manipulation of fire safety testing, misrepresentation of test data and misleading of the market.
Arconic and insulation firms Kingspan and Celotex came in for particularly heavy criticism.
Arconic was found to have 'deliberately concealed from the market the true extent of the danger' of using its cladding product, particularly on high-rise buildings.
Kingspan had, from 2005 and even after the inquiry began, 'knowingly created a false market in insulation' for use on buildings over 18 metres, the report said.
Celotex then, in an attempt to break into this market created by Kingspan, 'embarked on a dishonest scheme to mislead its customers and the wider market', Sir Martin concluded.
The Cabinet Office confirmed in February that seven companies were facing possible bans – Arconic, Kingspan, former Celotex owners Saint-Gobain, fire inspectors Exova, design and build contractor Rydon, architect Studio E and subcontractor Harley Facades.
Investigations were launched by the Government in March, assessing whether any engaged in professional misconduct for the purposes of the Procurement Act 2023, potentially leading them to be debarred from public contracts.
Questioning the Government over progress on work to remove unsafe cladding from high-rise buildings, Lord Rooker said: 'Can we be assured that the companies identified in the Grenfell report as using dishonest strategies and making false claims, such as Kingspan, Celotex and Arconic, are not involved in any replacement work?
'The companies are reported to have manipulated test data and manipulated the market.'
Speaking in the Lords chamber, where his comments are protected by parliamentary privilege, the peer added: 'The minister and other members will have read the exposure of the crooks running Arconic in a devastating article in the Sunday Times two days ago. Why are these people not behind bars?'
Responding, communities minister Lord Khan of Burnley said: 'The Cabinet Office announced investigations into seven organisations, a few of which he mentioned.
'These organisations were named in the Grenfell Tower Inquiry report, enabled by the Procurement Act 2023, which came into force on February 24 2025.
'The Cabinet Office is considering options under this Act. This is rightly independent.
'While this process must run its course, further actions outside the debarments regime against those involved in this tragedy have not been ruled out.'
Arconic have been contacted for comment.
Responding to the inquiry report last year, the firm said it was its subsidiary, Arconic Architectural Products SAS (AAP), which had supplied the material used for cladding in the tower's refurbishment, and that it rejects 'any claim that AAP sold an unsafe product' and that it 'did not conceal information from or mislead any certification body, customer, or the public'.
Kingspan said it had 'long acknowledged the wholly unacceptable historical failings that occurred in part of our UK insulation business' but said these were 'in no way reflective of how we conduct ourselves as a group, then or now'.
Celotex said it had 'reviewed and improved process controls, quality management and the approach to marketing within the Celotex business to meet industry best practice'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
29 minutes ago
- Indianapolis Star
Brenmiller Energy Appoints Boaz Toshav to Serve as an Independent Director on the Board
Experienced Global Investment Executive and Strategic Advisor to Support the Company's Next Phase of Growth ROSH HA'AYIN, IL / ACCESS Newswire Brenmiller Energy Ltd. ('Brenmiller', 'Brenmiller Energy', or the 'Company') (Nasdaq:BNRG), a leading global provider of Thermal Energy Storage (TES) solutions for industrial and utility customers, today announced the appointment of Mr. Boaz Toshav as an Independent Director to its Board of Directors (the 'Board'), effective immediately. Mr. Toshav previously served on the Company's Board from June 2023 until August 2024. Mr. Toshav has over 20 years of experience in investment banking, fixed income and mergers and acquisitions advisory services. He is currently President and Chairman of Rio Ave FC (Primeira Liga), a professional Portuguese football (soccer) club, and he previously served as a senior financial advisor to UK-based Nottingham Forest FC and Greece-based Olympiacos FC. Mr. Toshav also currently serves as the Chief Executive Officer of Umbrella Advisors Ltd., a boutique investment bank and financial advisory firm he founded in 2014. Mr. Toshav has also been a board member of Intelicanna Ltd. (TASE: INTL) and Getruck Ltd. since 2018 and 2021, respectively. Mr. Toshav received a Bachelor of Arts degree in Economics and Business Administration from Tel Aviv University, as well as a Master of Philosophy from Tel Aviv University. Mr. Toshav qualified as a United Kingdom Financial Services Authority certified investment advisor in 2005. 'We are honored to welcome Boaz back to our Board,' said Avi Brenmiller, Chairman and Chief Executive Officer of Brenmiller Energy. 'His proven ability to navigate financial markets, advise boards, and drive strategic partnerships will be instrumental as we enter a pivotal moment in our Company's evolution. With multiple commercial projects underway and a growing global footprint, we believe that Boaz's appointment will strengthen our governance and position us to realize significant value creation for our shareholders.' Mr. Toshav succeeds Ms. Nava Swersky Sofer, who concluded her term on the Board following six years of dedicated service. Ms. Swersky Sofer's departure was in accordance with the natural expiration of her term and was not the result of any disagreement with the Company. The Board and management extend their sincere appreciation for her strategic insight and leadership during a period of meaningful growth and transformation at Brenmiller Energy. This appointment follows Brenmiller's recent strategic milestones, including project deployments in Europe, Israel, and the United States. Notably, the European Hydrogen Bank has granted SolWinHy Cádiz S.L. (the 'SolWinHy Project') in Arcos de la Frontera, Spain, €25 million in funding. SolWinHy is a special purpose company jointly owned by leading renewable energy developers Green Enesys Group ('Green Enesys') and Viridi RE ('Viridi') to build new green hydrogen and green e-methanol projects in Europe. Green Enesys and Viridi are Brenmiller's joint venture partners in Brenmiller Europe S.L. ('Brenmiller Europe'). The Company estimates its supply of the bGen™ TES system for the SolWinHy Project to be approximately €7 million. The Company believes that its involvement with the SolWinHy Project reinforces the strength of its bGen™ technology and the Company's role in enabling renewable fuel production at scale. Brenmiller continues to expand its role as a key enabler of flexible, clean industrial heat in support of global net-zero targets. About Brenmiller Energy Ltd. Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller's patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers' needs. The most experienced thermal battery developer on the market, Brenmiller operates the world's only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company's website at and follow the company on X and LinkedIn. Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company uses forward-looking statements when it discusses: the Company's belief that Mr. Toshav's appointment will strengthen the Company's governance and position to realize significant value creation for shareholders; that the Company s entering a pivotal moment in its evolution; future commercial projects underway and a growing global footprint; the Company's estimates for its supply of the bGen™ TES system for the SolWinHy Project to be approximately €7 million; that the Company's involvement with the SolWinHy Project reinforces the strength of its bGen™ technology; the Company's role as a key enabler of flexible, clean industrial heat in support of global net-zero targets. Without limiting the generality of the foregoing, words such as 'plan,' 'project,' 'potential,' 'seek,' 'may,' 'will,' 'expect,' 'believe,' 'anticipate,' 'intend,' 'could,' 'estimate' or 'continue' are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company's results include, but are not limited to: the Company's planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission ('SEC') on March 4, 2025, which is available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Yahoo
32 minutes ago
- Yahoo
United States Diabetes Devices and Therapeutics Market Investment Opportunities Report 2025
The U.S. diabetes market is projected to grow at a CAGR of 7.2% from 2025-2029, reaching $39.33 billion. Key trends include real-time monitoring adoption, digital health integration, advanced delivery systems, and supportive regulatory frameworks. The report provides a data-centric analysis of market dynamics and opportunities. U.S. Diabetes Devices and Therapeutics Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "United States Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in United States is expected to grow by 8.4% on annual basis to reach US$27.62 billion in diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 9.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 25.47 billion to approximately USD 39.33 billion. The U.S. diabetes devices and therapeutics market is undergoing significant shifts with real-time monitoring, digital integration, advanced delivery systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures while emphasizing data integration and precise patient management. The U.S. diabetes devices and therapeutics market is characterized by a mix of established players and new entrants. Strategic partnerships, acquisitions, and the integration of digital health solutions are reshaping competitive dynamics. In the coming years, market consolidation and targeted innovation are expected to further define the competitive environment, influencing product offerings and patient management Adoption of Real-Time Glucose Monitoring U.S. healthcare providers increasingly use continuous glucose monitoring (CGM) systems to track patient glucose levels in real-time. Large healthcare networks have adopted CGM systems to support outpatient diabetes management. Recent publications indicate improvements in insurance reimbursement policies and favorable regulatory reviews. Enhanced clinical data on the reliability of CGM systems reinforces their use in routine diabetes care. Adoption is expected to increase, driven by wider coverage and enhanced device integration with electronic health records. The trend will likely intensify as more clinical studies validate the benefits of real-time monitoring in reducing long-term complications. Integrate Digital Health Solutions into Diabetes Management U.S. providers are integrating device data with telehealth platforms and remote patient monitoring systems for diabetes management. Examples include healthcare systems deploying centralized digital dashboards to monitor patient metrics remotely. Recent industry reports highlight a shift in healthcare delivery models that suggests a push toward digital transformation in chronic disease management. Insurance models increasingly support telehealth consultations and remote monitoring, aligning with broader medtech trends. The integration of digital platforms is expected to grow, promoting data-driven decision-making and enhancing care coordination. This trend will likely intensify, leading to a more efficient tracking of treatment adherence and patient outcomes. Advance Therapeutic Delivery Systems The market is witnessing the emergence of devices that support precise therapeutic delivery, such as smart insulin pens. U.S. manufacturers are introducing systems for accurate dosing and treatment adherence monitoring. Technological advancements in device miniaturization and data analytics are facilitating the development of these delivery systems. Recent healthcare publications note a rising focus on improving patient safety and treatment precision in diabetes care. Market penetration of smart delivery systems is expected to grow, influenced by evolving clinical practice guidelines and supportive reimbursement frameworks. This trend will intensify as precision therapy becomes a central focus in diabetes management. Regulatory and Reimbursement Frameworks Recent changes in FDA and CMS policies support integrating digital tools in diabetes care. Updated guidelines and expanded reimbursement criteria for digital health applications evidence these regulatory adjustments. Broader healthcare policy initiatives for cost containment and improved patient outcomes drive these regulatory changes. Publications from the past year highlight a response to the increased demand for remote monitoring and digital therapeutics. Regulatory support is expected to maintain momentum, enabling continued investment in digital health and advanced therapeutics. The framework will further intensify market adoption of compliant and data-integrated devices. Current Market ConditionsThe market comprises established manufacturers and emerging firms. A diverse portfolio of devices and therapeutics is present, ranging from established CGM systems to new smart delivery devices. Assess Key Competitors and Emerging Entrants Major companies, such as large medical device manufacturers and specialized diabetes care firms, hold significant market share. Established firms maintain comprehensive product portfolios covering both devices and therapeutics. New market entrants focus on integrating digital health solutions with diabetes management systems. These entrants bring targeted innovations, complementing the existing product mix in the U.S. market. Examine Strategic Partnerships and Corporate Activities Recent publications document acquisitions of smaller digital health companies by established device manufacturers. Strategic partnerships have been initiated between healthcare systems and technology firms to expand remote monitoring capabilities. The market shows signs of consolidation driven by competitive pressures and regulatory incentives. Collaborative efforts are aimed at enhancing integrated care delivery and data analytics capabilities. Future Competitive Dynamics Continued consolidation and strategic alliances are expected as established players seek to enhance their technological offerings. New entrants with digital health expertise will likely drive niche innovations, altering competitive positioning. Over the next 2-4 years, the competitive landscape will likely evolve with intensified competition and targeted market consolidation. Companies will increasingly leverage partnerships to improve patient data integration and therapeutic outcomes. Key Attributes: Report Attribute Details No. of Pages 50 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $29.83 Billion Forecasted Market Value (USD) by 2029 $39.33 Billion Compound Annual Growth Rate 7.2% Regions Covered United States ScopeDiabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
American Military News
33 minutes ago
- American Military News
Veteran Chinese dissident faces ongoing police harassment despite prison release
This article was originally published by Radio Free Asia and is reprinted with permission. Three months after his prison release, veteran dissident Chen Yunfei is in the cross-hairs of police over his social media posts and has faced multiple rounds of questioning and harassment amid ongoing surveillance, Radio Free Asia has learned. The Chengdu-based human rights activist and Chinese performance artist was released on March 24 after serving a four-year prison sentence in the southwestern province of Sichuan. But his friends say his freedom has been largely illusory, as police have repeatedly summoned him for interrogations and severely restricted his movements and ability to resume work. Chen has faced repeated persecution for his criticism of the Chinese Communist Party and commemoration of the 1989 Tiananmen protests, including demands that the government investigate the crackdown and compensate victims. In 2021, he was sentenced to four years in jail on of child molestation which he denied and said were intended to smear his reputation. Most recently, on the eve of the 36th anniversary of the June 4, 1989 Tiananmen Square protests crackdown, the National Security Bureau and local police subjected Chen to a five-hour interrogation, where he was forced to sit on the 'tiger bench,' Chen's friend and colleague Guan told Radio Free Asia on Wednesday. 'Tiger bench' is a form of torture used to restrain and immobilize detainees during questioning. Chen, like many others RFA interviewed for this story, asked to be identified only by a single name for fear of reprisals. 'The police accused him of 'picking quarrels and provoking trouble,'' said Guan, referring to a criminal charge frequently used by Chinese authorities to carry out arbitrary detentions against rights activists and dissidents. The charges were based on Chen's social media activity, including reposts of tweets by Ming Chu-cheng, an honorary professor of politics at National Taiwan University, and prominent dissidents Pastor Wang Yi, the pastor of a banned Protestant church in Chengdu, and citizen journalist Cai Chu, said Guan. Despite the lack of a subpoena, the police summoned Chen for questioning, confiscating his mobile phone and Wi-Fi equipment for three days, before returning them on June 3 night after repeated protests, Guan said. Chen's livelihood has also been impacted, his friends said. Upon release from prison, Chen found that his nursery business, which he had operated for many years, was emptied of all assets, causing him to lose his source of income, said Yang, another friend of the activist. The courts have also listed him as a 'dishonest debtor,' preventing him from accessing his bank accounts or resuming work, Yang said. 'He now has difficulty even renting a house and can only survive on donations from friends and through loans,' said Fang Liang, another friend of Chen's. During Chen's most recent imprisonment, his 91-year-old mother was also forcibly and violently removed from her Chengdu rental home by community workers, during which she suffered a head injury that required over a month of hospitalization, Guan said. During the forced eviction, many of the family's assets of value disappeared, including $30,000 of pension money that his mother had set aside for her granddaughter's education abroad, $5,800 in cash, and about 40,000 yuan (or US$5,560) in Chinese currency, Guan said. When Chen attempted to file a police report after discovering his empty home upon release, authorities refused to issue a receipt or open an investigation, said Yang. 'They don't allow you to have any evidence to sue them,' said Yang. 'The government said it's not their responsibility, and the police said to contact the community — they just pushed the matter back and forth.' Despite the ongoing harassment, Chen's friends say he is preparing to file a civil lawsuit to recover his mother's lost property and challenge the police's abuse of power. Shandong-based legal scholar Lu described Chen's ongoing troubles as a consequence of a typical 'secondary punishment' model that is designed to maintain control over dissidents through non-judicial means. 'Administrative review is inactive, the police deliberately do not issue receipts, and elderly mothers are forced to become homeless,' Lue said 'This is not law enforcement, but political coercion.'
